Zelandopam free base
| Code | Size | Price |
|---|
| TAR-T29213-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T29213-50mg | 50mg | £1,661.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T29213-100mg | 100mg | £2,079.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Zelandopam is a dopamine D1 agonist. Zelandopam is a potent stimulant of pancreatic exocrine secretion by acting on DA D1 receptors of the pancreas in dogs. Intravenous administration of Zelandopam produces renal vasodilating and diuretic/natriuretic effects by stimulation of dopamine D1 receptors, and demonstrate that Zelandopam can inhibit angiotensin II-, renal nerve stimulation- and PAF-induced renal dysfunction.
CAS:
139233-53-7
Formula:
C15H15NO4
Molecular Weight:
273.288
Purity:
0.98
SMILES:
Oc1ccc(cc1O)[C@@H]1CNCc2c(O)c(O)ccc12
References
1. Yatsu T, Aoki M, Tanaka A. Effect of zelandopam, a dopamine D1-like receptor agonist, in puromycin aminonucleoside nephrosis rats. Eur J Pharmacol. 2005 Mar 7;510(1-2):121-6. PubMed PMID: 15740732.
2. Yatsu T, Aoki M, Inagaki O. Preventive effect of zelandopam, a dopamine D1 receptor agonist, on cisplatin-induced acute renal failure in rats. Eur J Pharmacol. 2003 Feb 14;461(2-3):191-5. PubMed PMID: 12586214.
3. Yasunari K, Kohno M, Kano H, Hanehira T, Minami M, Yoshikawa J. Anti-atherosclerotic action of vascular D1 receptors. Clin Exp Pharmacol Physiol Suppl. 1999 Apr;26:S36-40. Review. PubMed PMID: 10386252.
4. Yatsu T, Arai Y, Takizawa K, Kasai-Nakagawa C, Takanashi M, Uchida W, Inagaki O, Tanaka A, Takenaka T. Effect of YM435, a dopamine DA1 receptor agonist, in a canine model of ischemic acute renal failure. Gen Pharmacol. 1998 Nov;31(5):803-7. PubMed PMID: 9809482.